Previous close | 3.15 |
Open | 9.82 |
Bid | 8.50 |
Ask | 8.80 |
Strike | 235.00 |
Expiry date | 2024-07-19 |
Day's range | 7.90 - 9.82 |
Contract range | N/A |
Volume | |
Open interest | 88 |
Edwards Lifesciences stock rallied Monday on medtech giant Becton Dickinson's plan to buy a key division for $4.2 billion.
BD's (BDX) robust product portfolio raises optimism about the stock.
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Edwards Lifesciences (NYSE: EW), today announced a definitive agreement under which BD will acquire Edwards' Critical Care product group ("Critical Care"), a global leader in advanced monitoring solutions, for $4.2 billion in cash, unlocking new value creation opportunities and enhancing BD's portfolio of smart connected care solutions.